Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 12/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29216428 | 0.90 | NOTUM (0.58) | NOTUML3MBTL1MEN1KMT2AHSD17B3 | |
| SCHEMBL23799185 | 0.85 | NPC1 (0.49) | NOTUMNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL25014427 | 0.83 | NOTUM (0.47) | NOTUMNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL7163398 | 0.81 | NOTUM (0.69) | NOTUML3MBTL1HSD17B3GAACNR2 | |
| SCHEMBL19329573 | 0.80 | NOTUM (0.67) | NOTUMCYP11B2 | |
| SCHEMBL31389170 | 0.79 | NR1H2 (0.46) | NOTUMNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL23293654 | 0.79 | NR1H2 (0.46) | NOTUMNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL21232729 | 0.78 | NOTUM (0.63) | NOTUM | |
| SCHEMBL19219782 | 0.78 | NOTUM (0.63) | NOTUMNPC1HSD17B3GAA | |
| SCHEMBL12781789 | 0.78 | NOTUM (0.63) | NOTUMHSD17B3GAACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | claimed |
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-10-17 | — | — | US | disclosed |
| EP-4382514-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2024-06-12 | — | — | EP | disclosed |
| CN-118139847-A | Pyrimidine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023014022-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-02-09 | — | — | WO | disclosed |
| WO-2023287130-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | 한국화학연구원 | 2023-01-19 | — | — | WO | disclosed |
| US-7994333-B2 | Methods and compositions for selectin inhibition | WYETH LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994333-B2 | Methods and compositions for selectin inhibition | WYETH LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994333-B2 | Methods and compositions for selectin inhibition | WYETH LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090069564-A1 | Methods and Compositions for Selectin Inhibition | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| WO-1999014197-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-03-25 | — | — | WO | disclosed |
| US-5512590-A | PREVENTS DISORDER OF GABAERGIC TRANSMISSION | SYNTHELABO (FR) | 1996-04-30 | — | — | US | disclosed |
| EP-0682025-A1 | 5,6-dihydro-4H-imidazo 2',1':2,3 imidazo 4,5,1-ij quinoline and 4,5-dihydroimidazo 1,2-a pyrrolo 1,2,3-cd benzimidazol derivatives | SYNTHELABO (FR) | 1995-11-15 | — | — | EP | disclosed |
| US-5436250-A | Isatineoxime derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1995-07-25 | — | — | US | disclosed |
| US-5242918-A | Isatinoxime derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-09-07 | — | — | US | disclosed |
| WO-1993005043-A1 | NOVEL ISATINOXIME DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1993-03-18 | — | — | WO | disclosed |
| EP-0529636-A1 | Novel isatinoxime derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-03 | — | — | EP | disclosed |
| US-3983137-A | Process for preparing 3-(indol-3-yl)-dehydronaphthalide hydrochlorides | POLAROID CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
| US-3933854-A | CHEMICAL INTERMEDIATES FOR INDICATOR DYES | POLAROID CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069564-A1 | Methods and Compositions for Selectin Inhibition | SELP, SELE, SELL | NOTUM 2276/4885NPC1 2309/4885RAB9A 4455/4885 |
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | ERBB2, EGFR, DPYD | NOTUM 228/4885NPC1 3164/4885RAB9A 3780/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | NOTUM 3548/4885NPC1 523/4885RAB9A 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.